A Comparison of Liposomal Amphotericin B with Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Pregnancy in Sudan.

Hdl Handle:
http://hdl.handle.net/10144/19292
Title:
A Comparison of Liposomal Amphotericin B with Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Pregnancy in Sudan.
Authors:
Mueller, M; Balasegaram, M; Koummuki, Y; Ritmeijer, K; Santana, M R; Davidson, R N N
Journal:
The Journal of Antimicrobial Chemotherapy
Abstract:
OBJECTIVES: Little is known about the treatment of visceral leishmaniasis (VL) in pregnancy, especially in resource-poor settings. We present a series of pregnant women with VL treated with either sodium stibogluconate or liposomal amphotericin B (AmBisome), or both, in eastern Sudan over 16 months. METHODS: We did a retrospective analysis of all pregnant VL patients treated in the Médecins sans Frontières (MSF) Um el Kher centre between January 2004 and April 2005. We diagnosed VL with laboratory confirmation of clinical suspects, and recorded the outcomes of treatment for pregnant women and their foetuses. We carried out a manual search of relevant publications and a systematic search of the literature in the MEDLINE database. RESULTS: We treated 23 women with sodium stibogluconate, 4 with AmBisome and sodium stibogluconate and 12 with AmBisome alone. There were 13 (57%) spontaneous abortions in the sodium stibogluconate monotherapy group, and none in either of the other two groups. All spontaneous abortions occurred in the first two trimesters. All patients, except one in the sodium stibogluconate group who defaulted, were discharged as cured in good clinical condition. CONCLUSIONS: AmBisome treatment for VL appears to be safe and effective for pregnant women and their foetuses. We recommend the use of AmBisome as first-line treatment for these patients.
Affiliation:
Médecins sans Frontières, 67-74 Saffron Hill, London EC1N 8QX, UK.
Publisher:
Published by Oxford University Press
Issue Date:
Oct-2006
URI:
http://hdl.handle.net/10144/19292
DOI:
10.1093/jac/dkl342
PubMed ID:
16916865
Additional Links:
http://jac.oxfordjournals.org/cgi/content/full/58/4/811?ijkey=AUk/t.2Id5/xw&keytype=ref&siteid=jac
Language:
en
Description:
To access this article, click on "Additional Links"
ISSN:
0305-7453
Appears in Collections:
Health Politics

Full metadata record

DC FieldValue Language
dc.contributor.authorMueller, M-
dc.contributor.authorBalasegaram, M-
dc.contributor.authorKoummuki, Y-
dc.contributor.authorRitmeijer, K-
dc.contributor.authorSantana, M R-
dc.contributor.authorDavidson, R N N-
dc.date.accessioned2008-02-28T10:49:39Z-
dc.date.available2008-02-28T10:49:39Z-
dc.date.issued2006-10-
dc.identifier.citationA Comparison of Liposomal Amphotericin B with Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Pregnancy in Sudan. 2006, 58 (4):811-5 J. Antimicrob. Chemother.en
dc.identifier.issn0305-7453-
dc.identifier.pmid16916865-
dc.identifier.doi10.1093/jac/dkl342-
dc.identifier.urihttp://hdl.handle.net/10144/19292-
dc.descriptionTo access this article, click on "Additional Links"-
dc.description.abstractOBJECTIVES: Little is known about the treatment of visceral leishmaniasis (VL) in pregnancy, especially in resource-poor settings. We present a series of pregnant women with VL treated with either sodium stibogluconate or liposomal amphotericin B (AmBisome), or both, in eastern Sudan over 16 months. METHODS: We did a retrospective analysis of all pregnant VL patients treated in the Médecins sans Frontières (MSF) Um el Kher centre between January 2004 and April 2005. We diagnosed VL with laboratory confirmation of clinical suspects, and recorded the outcomes of treatment for pregnant women and their foetuses. We carried out a manual search of relevant publications and a systematic search of the literature in the MEDLINE database. RESULTS: We treated 23 women with sodium stibogluconate, 4 with AmBisome and sodium stibogluconate and 12 with AmBisome alone. There were 13 (57%) spontaneous abortions in the sodium stibogluconate monotherapy group, and none in either of the other two groups. All spontaneous abortions occurred in the first two trimesters. All patients, except one in the sodium stibogluconate group who defaulted, were discharged as cured in good clinical condition. CONCLUSIONS: AmBisome treatment for VL appears to be safe and effective for pregnant women and their foetuses. We recommend the use of AmBisome as first-line treatment for these patients.en
dc.language.isoenen
dc.publisherPublished by Oxford University Press-
dc.relation.urlhttp://jac.oxfordjournals.org/cgi/content/full/58/4/811?ijkey=AUk/t.2Id5/xw&keytype=ref&siteid=jac-
dc.rightsArchived on this site with kind permission from Oxford University Press and the British Society for Antimicrobial Chemotherapyen
dc.subject.meshAbortion, Spontaneousen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAmphotericin Ben
dc.subject.meshAnimalsen
dc.subject.meshAntimony Sodium Gluconateen
dc.subject.meshAntiprotozoal Agentsen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshHumansen
dc.subject.meshInfant, Newbornen
dc.subject.meshLeishmaniasis, Visceralen
dc.subject.meshMiddle Ageden
dc.subject.meshPregnancyen
dc.subject.meshPregnancy Complications, Parasiticen
dc.subject.meshSudanen
dc.subject.meshTreatment Outcomeen
dc.titleA Comparison of Liposomal Amphotericin B with Sodium Stibogluconate for the Treatment of Visceral Leishmaniasis in Pregnancy in Sudan.en
dc.contributor.departmentMédecins sans Frontières, 67-74 Saffron Hill, London EC1N 8QX, UK.en
dc.identifier.journalThe Journal of Antimicrobial Chemotherapyen

Related articles on PubMed

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.